ICON Public Limited Company

Equities

ICLR

IE0005711209

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2023-12-08 pm EST Intraday chart for ICON Public Limited Company 5-day change 1st Jan Change
272.46 USD +1.59% +1.15% +40.26%
This article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Let's party like it's 2021
ANALYST RECOMMENDATIONS : Adobe, Broadcom, Comcast, Fair Isaac, Salesforce...
Deutsche Bank Raises ICON Price Target to $320 From $295, Maintains Buy Rating MT
Data keeps fueling the momentum
ANALYST RECOMMENDATIONS : Blackrock, Costco, Dollar Tree, Duke Energy, Snowflake...
Transcript : ICON Public Limited Company Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-29-2023 12:30 PM CI
Transcript : ICON Public Limited Company Presents at 14th Annual Jefferies London Healthcare Conference 2023, Nov-14-2023 02:00 PM CI
All good things must come to an end
ANALYST RECOMMENDATIONS : Best Buy, Diageo, Eli Lilly, Estee Lauder, Home Depot...
ICON Seeks Acquisitions CI
Transcript : ICON Public Limited Company, Q3 2023 Earnings Call, Oct 26, 2023 CI
ICON Q3 Adjusted EPS, Revenue Rise; Full-Year Guidance Disclosed MT
Earnings Flash (ICLR) ICON Posts Q3 EPS $3.30, vs. Street Est of $3.28 MT
Earnings Flash (ICLR) ICON Posts Q3 Revenue $2.06B, vs. Street Est of $2.06B MT
Icon Public Limited Company Re-Affirms Earnings Guidance for the Full-Year 2023 CI
ICON Public Limited Company Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
ICON Public Limited Company acquired Philips Pharma Solutions. CI
Deutsche Bank Adjusts ICON Price Target to $295 From $300, Maintains Buy Rating MT
Baird Adjusts Price Target on ICON to $287 From $278, Keeps Outperform Rating MT
ICON plc Releases Expanded End-To-End Clinical Trial Tokenisation Solution CI
ICON Partners With US Government for Clinical Trial of Next-Generation COVID-19 Vaccine Candidates MT
ICON to partner with US govt agency to test COVID vaccine candidates RE
ICON to partner with US govt agency to test COVID-19 vaccine candidates RE
ICON plc Partners with the U.S. Biomedical Advanced Research and Development Authority to Execute Next Generation COVID-19 Vaccines Clinical Trial CI
UBS Adjusts ICON Price Target to $295 From $285, Maintains Buy Rating MT
Chart ICON Public Limited Company
More charts
ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors. Its sectors include Biosimilars, Biotech, Government and public health solutions, medical devices, pharmaceuticals and the IVDR journey.
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
272.46USD
Average target price
286.21USD
Spread / Average Target
+5.05%
Consensus
  1. Stock
  2. Equities
  3. Stock ICON Public Limited Company - Nasdaq
  4. News ICON Public Limited Company
  5. Earnings Flash (ICLR) ICON Reports Q2 Revenue $2.02B, vs. Street Est of $2.02B
The best tools reserved for subscribers to boost the performance of your investments!
Optimize my profits
fermer